Left atrial appendage occlusion (LAAO) has evolved from an experimental concept into a guideline-supported therapeutic option for stroke prevention in selected patients with atrial fibrillation [1]. This evolution has been driven primarily by endocardial devices, which now have substantial randomized and real-world evidence supporting their safety and efficacy [2], [3], [4], [5], [6]. Nevertheless, endocardial approaches inherently involve placement of a permanent intracardiac implant and require at least short-term antithrombotic therapy, features that remain clinically relevant limitations, particularly in patients with prohibitive bleeding risk. Against this background, the report of seven-year follow-up from the first-in-human experience with a percutaneous epicardial-only LAA closure system provides a timely and thought-provoking perspective [7].

Extended longitudinal follow-up in structural heart interventions is uncommon, and it is especially rare for early feasibility experiences. The authors are therefore to be commended for presenting outcomes that extend well beyond the peri-procedural and early post-implantation phases. While the cohort is necessarily small, the duration of observation offers insights that short-term studies cannot provide and invites renewed consideration of epicardial strategies as part of the broader LAAO landscape.

The conceptual appeal of epicardial-only LAA exclusion is rooted in its biological simplicity. By achieving mechanical exclusion of the appendage without leaving a foreign body within the left atrium, epicardial approaches aim to eliminate concerns related to device-related thrombus, late embolization, and the need for postprocedural anticoagulation. Surgical experience has long supported the plausibility of this strategy, and randomized data in the surgical setting have reinforced the potential clinical benefit of durable appendage exclusion [8]. Translating this principle into a minimally invasive percutaneous approach has therefore been an attractive goal, particularly for patients who cannot tolerate anticoagulant or antiplatelet therapy.